Galectin-3 and soluble suppression of tumorigenicity 2 (sST2) have emerged as biomarkers in heart failure (HF) for additive risk stratification of patients with acute and/or chronic HF [10–12]. The gene discussed is LGALS3; the disease is hydrops fetalis.